- $106.34bn
- $123.47bn
- €46.72bn
Brief: Sanofi: Rilzabrutinib Earns Orphan Drug Designation In Japan For Igg4-Related Disease
Brief: Sanofi Says Dupixent Was Recommended For EU Approval To Treat CSU In Children
Brief: EMA's CHMP Recommended Granting A Marketing Authorisation For Mcombriax
Brief: Sanofi: Acoziborole Winthrop Receives CHMP Positive Opinion
Novavax raises revenue forecast on boost from vaccine deals; shares soar (updated)
Novavax up after raising annual revenue forecast
Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals
Brief: Sanofi And Regeneron’S Dupixent Approved In The U.S. For Allergic Fungal Rhinosinusitis
Brief: Astellas & Vir Biotechnology Collaborate To Advance VIR-5500
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Merck rises as drugmaker revamps human health business
India amends tax treaty with France, revises dividend tax structure
Media: L'Oréal played a key role in Sanofi CEO ouster, successor pick - Bloomberg News
Europe Research Roundup: Accor, Jost Werke, Dassault Systemes
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions (updated)
Brief: Sanofi Says State's Intervention Has No Bearing On The Merits Of This Case, And Sanofi Is Zealously Defending Texas AG Litigation
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions
Brief: Texas AG Sues Sanofi For Illegally Giving Kickbacks To Doctors To Prescribe Co’s Drugs
Vaccine slump risks a downward financial spiral